{"protocolSection": {"identificationModule": {"nctId": "NCT00954122", "orgStudyIdInfo": {"id": "D1443L00074"}, "organization": {"fullName": "AstraZeneca", "class": "INDUSTRY"}, "briefTitle": "Efficacy and Safety of SEROQUEL Extended Release (XR) in Acute Schizophrenia", "officialTitle": "A 3 Weeks Open Label Study to Evaluate the Efficacy in Agitation and Safety of Quetiapine Fumarate XR in Treatment of Patients With Acute Schizophrenia"}, "statusModule": {"statusVerifiedDate": "2013-01", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2009-09"}, "primaryCompletionDateStruct": {"date": "2010-03", "type": "ACTUAL"}, "completionDateStruct": {"date": "2010-04", "type": "ACTUAL"}, "studyFirstSubmitDate": "2009-08-06", "studyFirstSubmitQcDate": "2009-08-06", "studyFirstPostDateStruct": {"date": "2009-08-07", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2011-05-18", "resultsFirstSubmitQcDate": "2013-01-07", "resultsFirstPostDateStruct": {"date": "2013-01-08", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2013-01-07", "lastUpdatePostDateStruct": {"date": "2013-01-08", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "AstraZeneca", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "The purpose of the study is to determine whether treatment with quetiapine XR (Seroquel XR) tablets for 3 weeks will improve their agitation when they have acute psychosis."}, "conditionsModule": {"conditions": ["Schizophrenia"], "keywords": ["Acute schizophrenia"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE4"], "designInfo": {"allocation": "NA", "interventionModel": "SINGLE_GROUP", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 35, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Quetiapine XR", "type": "EXPERIMENTAL", "description": "Quetiapine XR 300 mg on day 1, 600 mg on day 2, and 400-800 mg (at investigator's discretion) on day 3 and onwards.", "interventionNames": ["Drug: Quetiapine XR (Seroquel XR)"]}], "interventions": [{"type": "DRUG", "name": "Quetiapine XR (Seroquel XR)", "description": "Tablet, oral, once daily", "armGroupLabels": ["Quetiapine XR"], "otherNames": ["Seroquel XR"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change From Baseline in Positive and Negative Syndrome Scale Excited Component (PANSS-EC) Score", "description": "PANSS- Excited Component (EC) subscale score will be calculated by adding together the following item scores: excitement (positive subscale item 4); hostility (positive subscale item 7); tension (general subscale item 4); uncooperativeness (general subscale item 8); poor impulse control (general subscale item 14). This is rated on a 7-point Likert scale from 'absent' to 'extremely severe' (score range 5 to 35 points; mean scores = 20 points clinically corresponds to severe agitation). Lower value gives the better outcome.", "timeFrame": "Baseline and Day 21"}], "secondaryOutcomes": [{"measure": "Change From Baseline to Final Visit at Day 21 in PANSS Positive, General Psychopathological Scores.", "description": "Positive scale includes 7 Items (Delusions, Conceptual disorganization, Hallucinations, Hyperactivity, Grandiosity, Suspiciousness/persecution, Hostility)and is calculated by adding the positive subscale item scores. Minimum score is 7, maximum score is 49. General Psychopathology scale:16 items (Somatic concern, Anxiety, Guilt feelings, Tension, Mannerisms and posturing, Depression, Motor retardation, Uncooperativeness, Unusual thought content, Disorientation, Poor attention, Lack of judgment and insight, Disturbance of volition, Poor impulse control, Preoccupation, Active social avoidance). Minimum score is 16, maximum score is 112. The higher score- the worse outcome. The biggest reduction of score from baseline- a better efficacy.\n\nMeasure includes PANSS-Positive (range 8-30), PANSS-General Psychopathological (PANSS-G)(range 17-70), total PANSS score (range 37-143), PANSS aggression, hostility and depression cluster scores (range 4-19).", "timeFrame": "Baseline and Day 21"}, {"measure": "Change From Baseline to Final Visit at Day 21 in PANSS Negative, General Psychopathological Scores", "description": "Negative scale includes 7 items (Blunted affect, Emotional withdrawal, Poor rapport, Passive/apathetic social withdrawal, Difficulty in abstract thinking, Lack of spontaneity and flow of conversation, Stereotyped thinking)and is calculated by adding the negative subscale item scores. Minimum score is 7, maximum score is 49. General Psychopathology scale includes 16 Items (Somatic concern, Anxiety, Guilt feelings, Tension, Mannerisms and posturing, Depression, Motor retardation, Uncooperativeness, Unusual thought content, Disorientation, Poor attention, Lack of judgment and insight, Disturbance of volition, Poor impulse control, Preoccupation, Active social avoidance). Minimum score is 16, maximum score is 112. The higher score- the worse outcome. Measure includes PANSS-Negative (range 8-37), PANSS-General Psychopathological (PANSS-G)(range 17-70), total PANSS score (range 37-143), PANSS aggression, hostility and depression cluster scores (range 4-19).", "timeFrame": "Baseline and Day 21"}, {"measure": "Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score", "description": "Positive and Negative Syndrome Scale (PANSS) total score is a medical scale used for measuring symptom severity of patients with schizophrenia. It is calculated by adding together PANSS-Positive (minimum score = 7, maximum score = 49, PANSS-Negative (minimum score = 7, maximum score = 49), PANSS-General Psychopathological (PANSS-G) subscale scores (minimum score = 16, maximum score = 112), supplementary subscale item scores. The minimum is 30, maximum is 210. Total PANSS score classification: Mildly ill 58- 74, Moderately ill 75-94, Markly ill 95- 115, Severely ill \\>116.", "timeFrame": "Baseline and Day 21"}, {"measure": "Change From Baseline in Clinical Global Impression-Severity Scale (CGI-S)", "description": "Clinical Global Impression, Severity (CGI-S) is a single-item (7-point) scale that evaluates the overall severity of the subject's mental illness. A reduction in score indicates an improvement in the subject's condition. The CGI-S assessment should be based upon the subject's symptoms during the previous week.\n\nChange from baseline in CGI-S score is calculated by subtracting the CGI-S score at baseline from the CGI-S score at the relevant time point.", "timeFrame": "Baseline and Day 21"}, {"measure": "Change From Baseline in Absolute Clinical Global Impression-Improvement (CGI-I) Scale", "description": "Clinical Global Impression, Improvement (CGI-I) is a single-item (7-point) scale that evaluates the overall improvement in the subject's mental. A reduction in score indicates an improvement in the subject's condition. This assessment is based on the improvement since initiation of the study treatment.\n\nChange in CGI-I score is analyzed by comparing CSI-score at the relevant time point to the baseline CGI-I score.", "timeFrame": "Baseline and Day 21"}, {"measure": "Change of the Positive and Negative Syndrome Scale Excited Component (PANSS-EC) Score Compared From Baseline to Day 21.", "description": "Excited Component was used to evaluate the control of agitation and aggression in patients with schizophrenia.\n\nDifference in mean score at baseline and day 21 is used to assess the improvement. It is shown by reduction in mean score and confirmed by p value lower than 0,05.\n\nPositive and Negative Syndrome Scale Excited Component (PANSS-EC) is a subscale score which is calculated by adding together the following item scores: excitement (positive subscale item 4); hostility (positive subscale item 7); tension (general subscale item 4); uncooperativeness (general subscale item 8); poor impulse control (general subscale item 14).\n\nThis is rated on a 7-point Likert scale from 'absent' to 'extremely severe' (score range 5 to 35 points; mean scores = 20 points clinically corresponds to severe agitation).", "timeFrame": "Baseline and Day 21"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Requirement for treatment of acute episode of schizophrenia (according to DSM-IV diagnostic criteria)\n* PANSS total score of \u00b3 75\n* CGI \\> 4\n\nExclusion Criteria:\n\n* Any DSM-IV (Diagnostic and Statistical Manual of Mental Disorders 4th Edition) Axis I disorder not defined in the inclusion criteria\n* Patients who, in the opinion of the investigator, pose an imminent risk of suicide or a danger to self or others\n* Substance or alcohol dependence at enrollment", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "65 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Ahmad Hatim Sulaiman,, M Psyc", "affiliation": "University of Malaya", "role": "PRINCIPAL_INVESTIGATOR"}, {"name": "Badiah Yahya, MD", "affiliation": "Hospital Permai", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Research Site", "city": "Johor", "state": "Johor Bahru", "country": "Malaysia"}, {"facility": "Research Site", "city": "Kuala Lumpur", "country": "Malaysia", "geoPoint": {"lat": 3.1412, "lon": 101.68653}}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "40 patients enrolled, 35 patients randomised and 28 patients completed the study", "recruitmentDetails": "18 Years to 65 Years Male \\& Female Acte schizophrenia (DSM-IV) Positive and Negative Syndrome Scale (PANSS) score at least 75, Clinical Global Impression (CGI)", "groups": [{"id": "FG000", "title": "Quetiapine Fumarate XR", "description": "This is a one arm Study. Patients were on quetiapine XR 300 mg on day 1, 600 mg on day 2, and 400-800 mg (at investigator's discretion) on day 3 and onwards"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "35"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "28"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "7"}]}], "dropWithdraws": [{"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "5"}]}, {"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "1"}]}, {"type": "Safety Reason", "reasons": [{"groupId": "FG000", "numSubjects": "1"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Quetiapine Fumarate XR", "description": "This is a one arm Study. Patients were on quetiapine XR 300 mg on day 1, 600 mg on day 2, and 400-800 mg (at investigator's discretion) on day 3 and onwards"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "35"}]}], "measures": [{"title": "Age, Categorical", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "<=18 years", "measurements": [{"groupId": "BG000", "value": "0"}]}, {"title": "Between 18 and 65 years", "measurements": [{"groupId": "BG000", "value": "35"}]}, {"title": ">=65 years", "measurements": [{"groupId": "BG000", "value": "0"}]}]}]}, {"title": "Age Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "38.3", "spread": "11"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "11"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "24"}]}]}]}, {"title": "Region of Enrollment", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "Malaysia", "categories": [{"measurements": [{"groupId": "BG000", "value": "35"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change From Baseline in Positive and Negative Syndrome Scale Excited Component (PANSS-EC) Score", "description": "PANSS- Excited Component (EC) subscale score will be calculated by adding together the following item scores: excitement (positive subscale item 4); hostility (positive subscale item 7); tension (general subscale item 4); uncooperativeness (general subscale item 8); poor impulse control (general subscale item 14). This is rated on a 7-point Likert scale from 'absent' to 'extremely severe' (score range 5 to 35 points; mean scores = 20 points clinically corresponds to severe agitation). Lower value gives the better outcome.", "populationDescription": "ITT population, which comprise of patients who have baseline and at least ONE (1) set of post-baseline PANSS assessments. No imputation on PANSS-EC score.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Scores on a scale", "timeFrame": "Baseline and Day 21", "groups": [{"id": "OG000", "title": "Quetiapine Fumarate XR", "description": "Patients were on quetiapine XR 300 mg on day 1, 600 mg on day 2, and 400-800 mg (at investigator's discretion) on day 3 and onwards"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "35"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-7.5", "spread": "4"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline to Final Visit at Day 21 in PANSS Positive, General Psychopathological Scores.", "description": "Positive scale includes 7 Items (Delusions, Conceptual disorganization, Hallucinations, Hyperactivity, Grandiosity, Suspiciousness/persecution, Hostility)and is calculated by adding the positive subscale item scores. Minimum score is 7, maximum score is 49. General Psychopathology scale:16 items (Somatic concern, Anxiety, Guilt feelings, Tension, Mannerisms and posturing, Depression, Motor retardation, Uncooperativeness, Unusual thought content, Disorientation, Poor attention, Lack of judgment and insight, Disturbance of volition, Poor impulse control, Preoccupation, Active social avoidance). Minimum score is 16, maximum score is 112. The higher score- the worse outcome. The biggest reduction of score from baseline- a better efficacy.\n\nMeasure includes PANSS-Positive (range 8-30), PANSS-General Psychopathological (PANSS-G)(range 17-70), total PANSS score (range 37-143), PANSS aggression, hostility and depression cluster scores (range 4-19).", "populationDescription": "ITT population, which comprise of patients who have baseline and at least ONE (1) set of post-baseline PANSS assessments. No imputation on PANSS Negative score.", "reportingStatus": "POSTED", "anticipatedPostingDate": "2011-04", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Scores on a scale", "timeFrame": "Baseline and Day 21", "groups": [{"id": "OG000", "title": "Quetiapine Fumarate XR", "description": "This is a one arm Study. Patients were on quetiapine XR 300 mg on day 1, 600 mg on day 2, and 400-800 mg (at investigator's discretion) on day 3 and onwards"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "35"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-9.3", "spread": "5.5"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline to Final Visit at Day 21 in PANSS Negative, General Psychopathological Scores", "description": "Negative scale includes 7 items (Blunted affect, Emotional withdrawal, Poor rapport, Passive/apathetic social withdrawal, Difficulty in abstract thinking, Lack of spontaneity and flow of conversation, Stereotyped thinking)and is calculated by adding the negative subscale item scores. Minimum score is 7, maximum score is 49. General Psychopathology scale includes 16 Items (Somatic concern, Anxiety, Guilt feelings, Tension, Mannerisms and posturing, Depression, Motor retardation, Uncooperativeness, Unusual thought content, Disorientation, Poor attention, Lack of judgment and insight, Disturbance of volition, Poor impulse control, Preoccupation, Active social avoidance). Minimum score is 16, maximum score is 112. The higher score- the worse outcome. Measure includes PANSS-Negative (range 8-37), PANSS-General Psychopathological (PANSS-G)(range 17-70), total PANSS score (range 37-143), PANSS aggression, hostility and depression cluster scores (range 4-19).", "populationDescription": "ITT population, which comprise of patients who have baseline and at least ONE (1) set of post-baseline PANSS assessments. No imputation on PANSS Positive score.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Scores on a scale", "timeFrame": "Baseline and Day 21", "groups": [{"id": "OG000", "title": "Quetiapine Fumarate XR", "description": "This is a one arm Study. Patients were on quetiapine XR 300 mg on day 1, 600 mg on day 2, and 400-800 mg (at investigator's discretion) on day 3 and onwards"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "35"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-5.7", "spread": "4.9"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score", "description": "Positive and Negative Syndrome Scale (PANSS) total score is a medical scale used for measuring symptom severity of patients with schizophrenia. It is calculated by adding together PANSS-Positive (minimum score = 7, maximum score = 49, PANSS-Negative (minimum score = 7, maximum score = 49), PANSS-General Psychopathological (PANSS-G) subscale scores (minimum score = 16, maximum score = 112), supplementary subscale item scores. The minimum is 30, maximum is 210. Total PANSS score classification: Mildly ill 58- 74, Moderately ill 75-94, Markly ill 95- 115, Severely ill \\>116.", "populationDescription": "ITT population, which comprise of patients who have baseline and at least ONE (1) set of post-baseline PANSS assessments. No imputation on PANSS Total score.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Scores on a scale", "timeFrame": "Baseline and Day 21", "groups": [{"id": "OG000", "title": "Quetiapine Fumarate XR", "description": "This is a one arm Study. Patients were on quetiapine XR 300 mg on day 1, 600 mg on day 2, and 400-800 mg (at investigator's discretion) on day 3 and onwards"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "35"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-33.2", "spread": "21.3"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Clinical Global Impression-Severity Scale (CGI-S)", "description": "Clinical Global Impression, Severity (CGI-S) is a single-item (7-point) scale that evaluates the overall severity of the subject's mental illness. A reduction in score indicates an improvement in the subject's condition. The CGI-S assessment should be based upon the subject's symptoms during the previous week.\n\nChange from baseline in CGI-S score is calculated by subtracting the CGI-S score at baseline from the CGI-S score at the relevant time point.", "populationDescription": "ITT population, which comprise of patients who have baseline and at least ONE (1) set of post-baseline PANSS (Positive and Negative Syndrome Scale) assessments. No imputation on CGI-S score.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "scores on a scale", "timeFrame": "Baseline and Day 21", "groups": [{"id": "OG000", "title": "Quetiapine Fumarate XR", "description": "This is a one arm Study. Patients were on quetiapine XR 300 mg on day 1, 600 mg on day 2, and 400-800 mg (at investigator's discretion) on day 3 and onwards"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "35"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-1.2", "spread": "0.9"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Absolute Clinical Global Impression-Improvement (CGI-I) Scale", "description": "Clinical Global Impression, Improvement (CGI-I) is a single-item (7-point) scale that evaluates the overall improvement in the subject's mental. A reduction in score indicates an improvement in the subject's condition. This assessment is based on the improvement since initiation of the study treatment.\n\nChange in CGI-I score is analyzed by comparing CSI-score at the relevant time point to the baseline CGI-I score.", "populationDescription": "ITT population, which comprise of patients who have baseline and at least ONE (1) set of post-baseline PANSS (Positive and Negative Syndrome Scale) assessments. No imputation on CGI-I score.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Scores on a scale", "timeFrame": "Baseline and Day 21", "groups": [{"id": "OG000", "title": "Quetiapine Fumarate XR", "description": "This is a one arm Study. Patients were on quetiapine XR 300 mg on day 1, 600 mg on day 2, and 400-800 mg (at investigator's discretion) on day 3 and onwards"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "35"}]}], "classes": [{"title": "Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "3.9", "spread": "0.4"}]}]}, {"title": "Day 21", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.4", "spread": "1.2"}]}]}]}, {"type": "SECONDARY", "title": "Change of the Positive and Negative Syndrome Scale Excited Component (PANSS-EC) Score Compared From Baseline to Day 21.", "description": "Excited Component was used to evaluate the control of agitation and aggression in patients with schizophrenia.\n\nDifference in mean score at baseline and day 21 is used to assess the improvement. It is shown by reduction in mean score and confirmed by p value lower than 0,05.\n\nPositive and Negative Syndrome Scale Excited Component (PANSS-EC) is a subscale score which is calculated by adding together the following item scores: excitement (positive subscale item 4); hostility (positive subscale item 7); tension (general subscale item 4); uncooperativeness (general subscale item 8); poor impulse control (general subscale item 14).\n\nThis is rated on a 7-point Likert scale from 'absent' to 'extremely severe' (score range 5 to 35 points; mean scores = 20 points clinically corresponds to severe agitation).", "populationDescription": "ITT population, which comprise of patients who have baseline and at least ONE (1) set of post-baseline PANSS assessments. No imputation on Outcome Measurement.", "reportingStatus": "POSTED", "anticipatedPostingDate": "2011-04", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Scores on a scale", "timeFrame": "Baseline and Day 21", "groups": [{"id": "OG000", "title": "Quetiapine Fumarate XR", "description": "This is a one arm Study. Patients were on quetiapine XR 300 mg on day 1, 600 mg on day 2, and 400-800 mg (at investigator's discretion) on day 3 and onwards"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "35"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-33.2", "spread": "21.3"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "eventGroups": [{"id": "EG000", "title": "Quetiapine Fumarate XR", "description": "This is a one arm Study. Patients were on quetiapine XR 300 mg on day 1, 600 mg on day 2, and 400-800 mg (at investigator's discretion) on day 3 and onwards", "seriousNumAffected": 1, "seriousNumAtRisk": 35, "otherNumAffected": 0, "otherNumAtRisk": 35}], "seriousEvents": [{"term": "Hospitalization", "organSystem": "Psychiatric disorders", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 35}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true}, "pointOfContact": {"title": "Gerard Lynch", "organization": "AstraZeneca", "email": "clinicaltrialtransparency@astrazeneca.com", "phone": "4415 09645895"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-26"}, "conditionBrowseModule": {"meshes": [{"id": "D000012559", "term": "Schizophrenia"}], "ancestors": [{"id": "D000019967", "term": "Schizophrenia Spectrum and Other Psychotic Disorders"}, {"id": "D000001523", "term": "Mental Disorders"}], "browseLeaves": [{"id": "M15376", "name": "Schizophrenia", "asFound": "Schizophrenia", "relevance": "HIGH"}, {"id": "M14452", "name": "Psychomotor Agitation", "relevance": "LOW"}, {"id": "M4815", "name": "Mental Disorders", "relevance": "LOW"}, {"id": "M14473", "name": "Psychotic Disorders", "relevance": "LOW"}, {"id": "M21838", "name": "Schizophrenia Spectrum and Other Psychotic Disorders", "relevance": "LOW"}, {"id": "T170", "name": "Acute Graft Versus Host Disease", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BXM", "name": "Behaviors and Mental Disorders"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC10", "name": "Nervous System Diseases"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}, {"abbrev": "Rare", "name": "Rare Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000069348", "term": "Quetiapine Fumarate"}], "ancestors": [{"id": "D000000928", "term": "Antidepressive Agents"}, {"id": "D000011619", "term": "Psychotropic Drugs"}, {"id": "D000014150", "term": "Antipsychotic Agents"}, {"id": "D000014149", "term": "Tranquilizing Agents"}, {"id": "D000002492", "term": "Central Nervous System Depressants"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}], "browseLeaves": [{"id": "M399", "name": "Quetiapine Fumarate", "asFound": "Modulated", "relevance": "HIGH"}, {"id": "M4247", "name": "Antidepressive Agents", "relevance": "LOW"}, {"id": "M14474", "name": "Psychotropic Drugs", "relevance": "LOW"}, {"id": "M16904", "name": "Antipsychotic Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "CNSDep", "name": "Central Nervous System Depressants"}, {"abbrev": "PsychDr", "name": "Psychotropic Drugs"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}